(ARKG) ARK Genomic Revolution - BATS
ETF Category: Health | Exchange: BATS (USA) | Market Cap: 1.260m USD | Total Return: 54.4% in 12m
Avg Turnover: 111M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The ARK Genomic Revolution ETF (ARKG) is an actively managed, non-diversified fund that allocates at least 80% of its assets to global equities aligned with advancements in genomics. Its portfolio spans healthcare, information technology, and materials, focusing on companies that integrate biological science with data computing to transform medical treatments.
The genomics sector relies on a business model centered on high research and development (R&D) intensity and intellectual property acquisition. These companies often utilize CRISPR gene-editing technology and bioinformatics to transition from traditional symptom management toward curative molecular therapies.
Investors seeking deeper insights into the underlying fundamentals of these holdings should consult ValueRay for further analysis.
- FDA approval timelines for gene therapies drive volatile portfolio valuations
- High interest rates increase capital costs for pre-revenue biotech holdings
- Breakthroughs in CRISPR and synthetic biology accelerate clinical trial pipelines
- Medicare reimbursement policy changes impact commercialization of genomic testing
- Strategic mergers and acquisitions activity provides liquidity and premium exits
As of June 23, 2026, the stock is trading at USD 36.40 with a total of 4,777,015 shares traded. Over the past week, the price has changed by +8.75%, over one month by +18.68%, over three months by +36.69% and over the past year by +54.37%.
Current recommended Stop Loss: 34.50 (which is 5.2% or 1.2 ATR below the current price).
ARK Genomic Revolution has no consensus analysts rating.